Literature DB >> 22057439

Autoreactivity against myelin basic protein in patients with chronic paraplegia.

D Zajarías-Fainsod1, J Carrillo-Ruiz, H Mestre, I Grijalva, I Madrazo, A Ibarra.   

Abstract

INTRODUCTION: Previous studies have shown the existence of either cellular or humoral MBP-reactive elements up to 5 years after spinal cord injury (SCI), but not the presence of both after 10 years.
MATERIALS AND METHODS: Twelve SCI patients, with more than 10 years of evolution, and 18 healthy blood donors were studied. Lymphocyte proliferation (colorimetric-BrdU ELISA assay) and antibody titers against MBP (ELISA Human IgG MBP-specific assay) were assessed.
RESULTS: SCI patients presented a significant T-cell proliferation against MBP (lymphocyte proliferation index: 3.7 ± 1.5, mean ± SD) compared to control individuals (0.7 ± 0.3; P < 0.001). Humoral response analysis yielded a significant difference (P < 0.0001) between the antibody titers of controls and SCI patients. A significant correlation between cellular and humoral responses was observed. Finally, patients with an ASIA B presented the highest immune responses.
CONCLUSION: This work demonstrates, for the first time, the existence of both cellular and humoral responses against MBP in the chronic stages (>10 years) of injury.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22057439      PMCID: PMC3337920          DOI: 10.1007/s00586-011-2060-7

Source DB:  PubMed          Journal:  Eur Spine J        ISSN: 0940-6719            Impact factor:   3.134


  18 in total

1.  Elevated serum titers of proinflammatory cytokines and CNS autoantibodies in patients with chronic spinal cord injury.

Authors:  K C Hayes; T C L Hull; G A Delaney; P J Potter; K A J Sequeira; K Campbell; P G Popovich
Journal:  J Neurotrauma       Date:  2002-06       Impact factor: 5.269

Review 2.  Glatiramer acetate treatment of multiple sclerosis: an immunological perspective.

Authors:  Michael K Racke; Amy E Lovett-Racke
Journal:  J Immunol       Date:  2011-02-15       Impact factor: 5.422

3.  Immunization with neural-derived antigens inhibits lipid peroxidation after spinal cord injury.

Authors:  Antonio Ibarra; Elisa García; Nayeli Flores; Susana Martiñón; Rafael Reyes; María G Campos; Marcial Maciel; H Mestre
Journal:  Neurosci Lett       Date:  2010-04-08       Impact factor: 3.046

Review 4.  Concept of autoimmunity following spinal cord injury: possible roles for T lymphocytes in the traumatized central nervous system.

Authors:  P G Popovich; B T Stokes; C C Whitacre
Journal:  J Neurosci Res       Date:  1996-08-15       Impact factor: 4.164

5.  Systemic humoral factors participating in the course of spinal cord injury.

Authors:  Y Mizrachi; A Ohry; A Aviel; R Rozin; M E Brooks; M Schwartz
Journal:  Paraplegia       Date:  1983-10

6.  T cell responses to myelin basic protein in patients with spinal cord injury and multiple sclerosis.

Authors:  K Kil; Y C Zang; D Yang; J Markowski; G S Fuoco; G C Vendetti; V M Rivera; J Z Zhang
Journal:  J Neuroimmunol       Date:  1999-08-03       Impact factor: 3.478

7.  Pathological CNS autoimmune disease triggered by traumatic spinal cord injury: implications for autoimmune vaccine therapy.

Authors:  T Bucky Jones; D Michele Basso; Ajeet Sodhi; Jonathan Z Pan; Ronald P Hart; Robert C MacCallum; Sunhee Lee; Caroline C Whitacre; Phillip G Popovich
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

8.  Effects of cyclosporin-A on immune response, tissue protection and motor function of rats subjected to spinal cord injury.

Authors:  Antonio Ibarra; Dolores Correa; Kaethe Willms; Marie Therese Merchant; Gabriel Guizar-Sahagún; Israel Grijalva; Ignacio Madrazo
Journal:  Brain Res       Date:  2003-07-25       Impact factor: 3.252

9.  Therapeutic vaccination for closed head injury.

Authors:  Jonathan Kipnis; Uri Nevo; David Panikashvili; Alexander Alexandrovich; Eti Yoles; Solange Akselrod; Esther Shohami; Michal Schwartz
Journal:  J Neurotrauma       Date:  2003-06       Impact factor: 5.269

10.  An investigation of auto-reactivity after head injury.

Authors:  A L Cox; A J Coles; J Nortje; P G Bradley; D A Chatfield; S J Thompson; D K Menon
Journal:  J Neuroimmunol       Date:  2006-03-06       Impact factor: 3.478

View more
  15 in total

1.  Spinal cord injury-induced immune deficiency syndrome enhances infection susceptibility dependent on lesion level.

Authors:  Benedikt Brommer; Odilo Engel; Marcel A Kopp; Ralf Watzlawick; Susanne Müller; Harald Prüss; Yuying Chen; Michael J DeVivo; Felix W Finkenstaedt; Ulrich Dirnagl; Thomas Liebscher; Andreas Meisel; Jan M Schwab
Journal:  Brain       Date:  2016-01-10       Impact factor: 13.501

2.  B Cell-Activating Factor Is Associated with Testosterone and Smoking Status in Non-Ambulatory Men with Chronic Spinal Cord Injury.

Authors:  Ricardo A Battaglino; Nguyen Nguyen; Megan Summers; Leslie R Morse
Journal:  J Neurotrauma       Date:  2019-06-17       Impact factor: 5.269

Review 3.  The paradox of chronic neuroinflammation, systemic immune suppression, autoimmunity after traumatic chronic spinal cord injury.

Authors:  Jan M Schwab; Yi Zhang; Marcel A Kopp; Benedikt Brommer; Phillip G Popovich
Journal:  Exp Neurol       Date:  2014-08       Impact factor: 5.330

4.  Increased Levels of Circulating Glial Fibrillary Acidic Protein and Collapsin Response Mediator Protein-2 Autoantibodies in the Acute Stage of Spinal Cord Injury Predict the Subsequent Development of Neuropathic Pain.

Authors:  Georgene W Hergenroeder; John B Redell; H Alex Choi; Lisa Schmitt; William Donovan; Gerard E Francisco; Karl Schmitt; Anthony N Moore; Pramod K Dash
Journal:  J Neurotrauma       Date:  2018-07-05       Impact factor: 5.269

5.  B-cell maturation antigen, a proliferation-inducing ligand, and B-cell activating factor are candidate mediators of spinal cord injury-induced autoimmunity.

Authors:  Jonah W Saltzman; Ricardo A Battaglino; Loise Salles; Prateek Jha; Supreetha Sudhakar; Eric Garshick; Helen L Stott; Ross Zafonte; Leslie R Morse
Journal:  J Neurotrauma       Date:  2013-03-28       Impact factor: 5.269

Review 6.  The Next Generation of Biomarker Research in Spinal Cord Injury.

Authors:  Elke Ydens; Ilse Palmers; Sven Hendrix; Veerle Somers
Journal:  Mol Neurobiol       Date:  2016-02-05       Impact factor: 5.590

7.  B-Cell Depletion with CD20 Antibodies as New Approach in the Treatment of Inflammatory and Immunological Events Associated with Spinal Cord Injury.

Authors:  Giovanna Casili; Daniela Impellizzeri; Marika Cordaro; Emanuela Esposito; Salvatore Cuzzocrea
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

8.  Long-term production of BDNF and NT-3 induced by A91-immunization after spinal cord injury.

Authors:  Susana Martiñón; Elisa García-Vences; Diana Toscano-Tejeida; Adrian Flores-Romero; Roxana Rodriguez-Barrera; Manuel Ferrusquia; Rolando E Hernández-Muñoz; Antonio Ibarra
Journal:  BMC Neurosci       Date:  2016-06-30       Impact factor: 3.288

9.  Antibody profiling identifies novel antigenic targets in spinal cord injury patients.

Authors:  Ilse Palmers; Elke Ydens; Eric Put; Bart Depreitere; Helma Bongers-Janssen; Peter Pickkers; Sven Hendrix; Veerle Somers
Journal:  J Neuroinflammation       Date:  2016-09-13       Impact factor: 8.322

10.  Anterior chamber associated immune deviation used as a neuroprotective strategy in rats with spinal cord injury.

Authors:  Beatriz Pineda-Rodriguez; Diana Toscano-Tejeida; Elisa García-Vences; Roxana Rodriguez-Barrera; Adrian Flores-Romero; Daniela Castellanos-Canales; Gabriel Gutierrez-Ospina; Laura Castillo-Carvajal; Esperanza Meléndez-Herrera; Antonio Ibarra
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.